Want to see ALT full AI Analyst Report?
ALT Stock Chart & Stats
$2.77
-$0.07(-2.46%)
At close: 4:00 PM EDT
$2.77
-$0.07(-2.46%)
Day’s Range― - ―
52-Week Range$2.56 - $6.44
Previous CloseN/A
Volume1.91M
Average Volume (3M)4.02M
Market Cap
$573.83M
Enterprise Value$273.45
Total Cash (Recent Filing)$326.32M
Total Debt (Recent Filing)$35.75M
Price to Earnings (P/E)―
Beta1.57
Next Earnings
Nov 10, 2026EPS Estimate
-0.14Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.78
Shares Outstanding194,517,700
10 Day Avg. Volume2,499,239
30 Day Avg. Volume4,018,388
Financial Highlights & Ratios
PEG Ratio0.14
Price to Book (P/B)1.41
Price to Sales (P/S)7757.46
P/FCF Ratio-4.71
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$19.50Price Target Upside603.97% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)-0.59
Revenue Forecast (FY)$1.88K
Bulls Say, Bears Say
Bulls Say
MASH Phase III AdvancementStarting a global Phase III trial materially advances pemvidutide toward potential commercialization in MASH. Broad site coverage and a defined 52-week biopsy endpoint create a structured path to generating pivotal efficacy evidence.
Positive AUD And ALD Clinical ProgressClinical activity across AUD and ALD diversifies pemvidutide’s potential indications. Positive drinking-behavior, biomarker and weight-loss outcomes support differentiation, while completed ALD enrollment advances another important liver-disease catalyst.
Strong Capitalization And Low LeverageA well-capitalized, low-leverage balance sheet reduces near-term solvency pressure and supports continued investment in pivotal trials. Management says existing cash funds PERFORMA through its 52-week readout, improving development continuity.
Bears Say
Persistent Losses And Cash BurnAltimmune has negligible product revenue and a cost base dominated by research and development. Sustained annual cash outflows mean value creation depends on successful clinical development and eventual financing or commercialization.
Funding Gap For Potential AUD Phase IIIA pivotal AUD program would require additional capital beyond the currently funded MASH plan. Reliance on royalties, debt or partnerships introduces execution and dilution risk if non-dilutive funding is unavailable or delayed.
Clinical Execution And Tolerability RiskGastrointestinal tolerability could limit adherence or commercial uptake, while competing Phase III programs may slow enrollment and raise costs. Long timelines also leave substantial regulatory, efficacy and execution uncertainty before approval.
Altimmune News
ALT FAQ
What was Altimmune’s price range in the past 12 months?
Altimmune lowest stock price was $2.56 and its highest was $6.44 in the past 12 months.
What is Altimmune’s market cap?
Altimmune’s market cap is $573.83M.
When is Altimmune’s upcoming earnings report date?
Altimmune’s upcoming earnings report date is Nov 10, 2026 which is in 80 days.
How were Altimmune’s earnings last quarter?
Altimmune released its earnings results on Aug 12, 2026. The company reported -$0.12 earnings per share for the quarter, beating the consensus estimate of -$0.136 by $0.016.
Is Altimmune overvalued?
According to Wall Street analysts Altimmune’s price is currently Undervalued.
Does Altimmune pay dividends?
Altimmune pays a Monthly dividend of $873 which represents an annual dividend yield of N/A. See more information on Altimmune dividends here
What is Altimmune’s EPS estimate?
Altimmune’s EPS estimate is -0.14.
How many shares outstanding does Altimmune have?
Altimmune has 194,517,700 shares outstanding.
What happened to Altimmune’s price movement after its last earnings report?
Altimmune reported an EPS of -$0.12 in its last earnings report, beating expectations of -$0.136. Following the earnings report the stock price went down -2.333%.
Which hedge fund is a major shareholder of Altimmune?
Currently, no hedge funds are holding shares in ALT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Altimmune Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$19.50 (603.97% Upside)
$19.50 (603.97% Upside)
Blogger Sentiment
Bullish
ALT Sentiment 89%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 16.6M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $44.3K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 4.6%
Last 30 Days ▲ 10.7%
Last 30 Days ▲ 10.7%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-32.60%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
176.97%
Trailing 12-Months
Company Description
Altimmune
Altimmune, Inc. (ALT) is a clinical-stage biopharmaceutical company focused on developing peptide-based therapeutics for metabolic and liver diseases. Its pipeline includes investigational candidates such as pemvidutide, a GLP-1/glucagon dual receptor agonist being studied for obesity and metabolic dysfunction–associated steatohepatitis (MASH/NASH). The company’s operations primarily involve research and development activities and advancing product candidates through clinical trials rather than commercial product sales.
ALT Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed substantial clinical and operational momentum: initiation of a global Phase III in MASH, robust positive Phase II AUD data that met multiple registrational endpoints (including objective biomarker improvements and 9.1% weight loss), completed enrollment in ALD, and a strengthened balance sheet ($519M cash). Key positives notably outweigh near‑term risks, though important caveats remain — including higher operating expenses, GI-related tolerability signals under further review, a competitive MASH enrollment landscape, and the need to secure non-dilutive funding for a potential AUD Phase III (not covered by the current runway). Several pivotal readouts (RESTORE H2 2027, PERFORMA 52‑week in 2029) and regulatory engagements are upcoming and will be determinative for long-term value.View all ALT earnings summariesALT Stock 12 Month Forecast
Average Price Target
$19.50
▲(603.97% Upside)
Technical Analysis
Tvardi Therapeutics
―
Diamedica Therapeutics
―
Alpha Tau Medical Ltd
―
enGene Holdings
―
Lexeo Therapeutics, Inc.
―
Ownership Overview
0.42% Insiders
9.34% Mutual Funds
30.73% Other Institutional Investors
43.15% Public Companies and
Individual Investors